Table 2.

Patient characteristics in the chemotherapy + bevacizumab group.

Variable	Right-side colon	Left-side colon	P-value, chi-square
Number of patients	78	86
Age
≤50 y	41	41	0.598
51-65 y	25	34
>65 y	12	11
Sex
Male	44	56	0.266
Female	34	30
Mucinous histology
Yes	15	14	0.684
No	63	72
Stage at diagnosis
I	1	9	0.207
II	6	24
III	26	53
IV	45	86
Metastatic organ
1	59	61	0.597
>1	19	25
CEA
≤5 ng/ml	15	28	0.051
>5 ng/ml	63	56
unknown	0	2
LDH
≤245 U/ml	57	57	0.494
>245 U/ml	21	28
unknown	0	1
Backbone chemotherapy
Oxaliplatin-based	41	49	0.304
Irinotecan-based	37	35
5-fluorouracil only	0	2
Bevacizumab beyond first line
Yes	16	15	0.691
No	62	71
Cetuximab treated
Yes	7	13	0.245
No	71	73
Primary tumor resection
Yes	57	67	0.585
No	21	19